# Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

> **NCT03240393** · PHASE2 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Carcinoma
- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** INC280

## Key facts

- **NCT ID:** NCT03240393
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-07-31
- **Primary completion:** 2021-10-26
- **Final completion:** 2021-10-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company Decision
- **Last updated:** 2018-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03240393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03240393, "Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03240393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*